681-P: Effect of 3-Month Therapy with SGLT2 Inhibitors and GLP-1 Agonists on Ambulatory Blood Pressure in Patients with Type 2 Diabetes Mellitus

Abstract

Background and Aims: It is known that SGLT-2 inhibitors and GLP-1 agonists show a favorable profile in the reduction of body weight as well as blood pressure (BP). Therefore, the purpose of this study is to evaluate the effect of SGLT-2 inhibitors and GLP-1 agonists on ambulatory BP in patients with poorly controlled type 2 diabetes (T2D). Materials and Methods: A total of 74 patients with T2D: 42 on GLP-1 agonists (group Α) [20 men, mean age (±standard deviation) 60.6±9.4 years, HbA1c 8.5±1,1%, body mass index (BMI) 37.1±5.3 Kg/m2, T2D duration 10.1±4.3] and 32 on SGLT-2 inhibitors (group Β) [16 men, mean age 64.8±7.1 years, HbA1c 8.2±1.3%, BMI 32,1±9,2 Kg/m2]. All patients underwent a complete clinical and laboratory examination. Ambulatory BP recording at baseline and three months after initiation of treatment with the oscillometric Mobil-O-Graph NGW 24-hour ambulatory BP and PWA monitor (IEM; Stolberg, Germany). Results: At baseline, mean daytime systolic and diastolic BP in group A were: 128.0±11.2 and 77.2±11.0 mmHg and in group B: 129.6±14.8 and 78.1±9.9 mmHg, respectively (P=0.78 and P=0.81, respectively, for the comparison between the study groups). Regarding the nighttime recordings of BP in group A, mean systolic and diastolic BP were: 127.5±12.6 and 73.7±14.2 mmHg. In group B, mean systolic and diastolic BP were: 126.3±12.5 and 74.1±8.7 mmHg (P=0.57 and P=0.67, respectively, for the comparison between the study groups). After 3-month therapy, mean systolic BP (group A versus B) was 124.0±7.8 versus 128.2±10.4 mmHg (P=0.04) and mean diastolic BP, 73.5±7.8 versus 78.3±7.8 mmHg (P=0.05). Regarding nighttime systolic BP was 118.6±11.1 (group Α) versus 117.4±9.3 mmHg (group Β) (P=0.54) and for mean diastolic BP 68.1±9.8 (group Α) versus 69.6±7.1 mmHg (group Β) (P=0.69). Conclusion: Three-month therapy with GLP-1 agonists had a favorable effect of ambulatory systolic and diastolic BP compared to SGLT-2 inhibitors. Disclosure A. Papazafiropoulou: None. S. S. Papantoniou: None. M. Rallatou: None. A. J. Melidonis: None. S. Antonopoulos: None.